BidaskClub downgraded shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a report published on Thursday.
Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $37.00 price target on Audentes Therapeutics and gave the stock a buy rating in a research note on Thursday, January 4th. BMO Capital Markets set a $44.00 target price on Audentes Therapeutics and gave the company a buy rating in a research note on Friday, January 5th. William Blair reaffirmed a buy rating on shares of Audentes Therapeutics in a research note on Friday, January 5th. Zacks Investment Research raised Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 target price on the stock in a research note on Thursday, March 8th. Finally, Cowen reaffirmed a buy rating on shares of Audentes Therapeutics in a research note on Friday, March 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $35.56.
BOLD stock opened at $29.45 on Thursday. The firm has a market capitalization of $1,080.05, a PE ratio of -8.66 and a beta of 0.89. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $41.80.
In related news, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 421,638 shares of the business’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $35.17, for a total value of $14,829,008.46. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,087,707 shares of company stock worth $38,055,301. Company insiders own 47.30% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in shares of Audentes Therapeutics in the 3rd quarter valued at approximately $143,000. Nationwide Fund Advisors grew its stake in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Audentes Therapeutics in the 4th quarter valued at approximately $208,000. MetLife Investment Advisors LLC bought a new stake in shares of Audentes Therapeutics in the 4th quarter valued at approximately $248,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Audentes Therapeutics by 1,086.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 12,435 shares in the last quarter. 67.35% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3276434/audentes-therapeutics-bold-cut-to-buy-at-bidaskclub.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.